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A left jab followed quickly by a right cross 
(“the old one-two”) can be a powerful 
combination for knocking an opponent 
off his feet in the boxing ring. Likewise, 
hitting two cellular pathways implicated 
in a particular disease simultaneously 
can be an effective way of combating that 
disease, as exemplified by combination 
chemotherapy to treat cancer and antiret-
roviral drug cocktails for fighting AIDS. In 
the neurodegenerative disorder Alzheim-
er’s disease (AD), a key initiating patho-
genic event is the assembly of neurotoxic 
aggregates of the amyloid β-peptide 
(Aβ). This proteolytic fragment is cleaved 
from the membrane-bound amyloid pre-
cursor protein (APP) by the sequential 
action of β- and γ-secretases (Figure 1) 
(Hardy and Selkoe, 2002). Production of 
Aβ can be avoided if APP is cleaved first 
by α-secretase instead of by β-secretase. 
Current approaches to developing thera-
peutics for AD include reducing or clear-
ing Aβ using β- or γ-secretase inhibitors 
or immunotherapy, respectively, and 
enhancing neuronal protection and repair, 
for example, by boosting neurotrophic 
signaling with nerve growth factor. In this 
issue of Cell, Donmez et al. (2010) reveal a 
potential strategy for accomplishing both 
decreased Aβ production and increased 
neuronal repair by activating the deacety-
lase SIRT1, which helps to turn on the 
transcription factor retinoic acid receptor 
β (RARβ), thereby increasing expression 
of a key α-secretase.
Genetic, biochemical, and patho-
logical evidence, along with studies in 
mouse models, strongly implicate Aβ 
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A dual goal for treating Alzheimer’s disease (AD) is to decrease deposition of neurotoxic amyloid 
β-peptide in the brain and to boost repair of damaged neurons. Donmez et al. (2010) now show 
that SIRT1 may mediate both processes by deacetylating the transcription factor retinoic acid 
receptor β, a potential new therapeutic target for AD.
Figure 1. Proteolytic Processing of APP and Notch
(Left) The amyloid β-peptide (Aβ) that assembles into neurotoxic aggregates in the brain leading to Alzheimer’s disease (AD) is formed by the sequential cleav-
age of the amyloid precursor protein (APP) by the β- and γ-secretases. During this process, the amyloid intracellular domain (AICD) is also produced. Alterna-
tively, APP can be cleaved by α-secretases (including the metalloprotease ADAM10) within the Aβ region, thus precluding Aβ production.
(Right) The Notch receptor undergoes similar processing upon binding by ligand, with sequential cleavage by ADAM10 and γ-secretase. Release of the Notch 
intracellular domain (NICD) from the membrane results in Notch signaling and transcriptional activation that promotes neuronal repair. (Inset) Deacetylation of 
retinoic acid receptor β (RARβ) by SIRT1 leads to activation of this transcription factor, which boosts expression of ADAM10. SIRT1-dependent activation of 
RARβ leads to increased ADAM10 activity, shunting APP away from Aβ production and the pathogenic events that lead to AD. An increase in ADAM10 also may 
boost cleavage of the Notch receptor, leading to increased Notch signaling and neuronal repair.
as an initiator of the AD pathogenic pro-
cess (Ashe and Zahs, 2010; Tanzi and 
Bertram, 2005). Deposition of Aβ into 
extracellular plaques in the brain and for-
mation of intraneuronal filaments com-
posed of hyperphosphorylated forms 
of the microtubule-associated protein 
tau are the signature characteristics of 
AD. Dominant missense mutations in the 
APP gene and in the presenilin genes 
PSEN1 and PSEN2 (which encode com-
ponents of γ-secretase) alter Aβ produc-
tion in a way that increases the peptide’s 
tendency to aggregate, resulting in rare 
familial forms of AD in mid-life. Inhibition 
of the proteases that produce Aβ is an 
obvious strategy for AD drug discovery, 
but blocking β- and γ-secretase activ-
ity may lead to side effects because of 
other substrates that they cleave (Cit-
ron, 2010). An indirect means of lower-
ing Aβ production is to stimulate alter-
native cleavage of APP (at a site within 
the Aβ region) by certain membrane-
tethered metalloproteases that serve as 
α-secretases (Figure 1). This has been 
accomplished in mice overexpressing 
APP by activating protein kinase C with 
selective muscarinic agonists (Caccamo 
et al., 2006), in particular those that tar-
get the M1 receptor subtype. This stim-
ulates cleavage of APP by α-secretase 
in appropriate regions of the brain and 
without the unacceptable side effects of 
broader muscarinic agonists.
Proteolysis of the Notch family of 
receptors, which are critical for many 
cell differentiation events, including 
those involved in neuronal development, 
follows a very similar course to that of 
APP (Figure 1) (Kopan and Ilagan, 2009). 
When the Notch receptor interacts with 
its ligand, the receptor is cleaved by an 
α-secretase called ADAM10 (which also 
cleaves APP), resulting in shedding of 
the Notch ectodomain (Figure 1). The 
remaining membrane-bound portion of 
the Notch receptor is further cleaved by 
γ-secretase to release the Notch intracel-
lular domain (NICD), which activates the 
Notch signaling pathway, ultimately turn-
ing on transcription factors that help to 
control cell fate. The main problem with 
γ-secretase as an AD drug target is the 
fact that its inhibition blocks Notch pro-
teolysis and signaling, with potentially 
severe consequences such as immune 
suppression and gastrointestinal toxic-
ity. In contrast, stimulating α-secretase 
cleavage of APP does not inhibit Notch 
signaling and may even enhance it.
In their new study, Donmez et al. 
(2010) now show that such a dual effect, 
stimulating α-secretase cleavage of 
both APP and Notch, is possible through 
the action of SIRT1. The sirtuin proteins 
are deacetylases that display antiaging 
properties in animal models, and SIRT1 
in particular can counter the effects 
of various forms of stress (Guarente, 
2007). Based on their long-standing 
interest in these phenomena, Donmez 
and colleagues set out to determine if 
SIRT1 could affect Aβ plaque forma-
tion, pathology, and cognitive decline in 
an AD mouse model. Their mice over-
expressed the human APP and PSEN1 
genes, both containing mutations known 
to cause familial AD, in the mouse brain. 
Crossing these APP/PSEN1 mice with 
mice that overexpressed SIRT1 in the 
brain resulted in offspring that showed 
a number of characteristics associ-
ated with a reduced risk of AD. The off-
spring showed reduced formation of Aβ 
plaques in the brain, a decrease in mark-
ers of brain inflammation, a decrease in 
the phosphorylation of certain sites in 
the tau protein, and rescue of the learn-
ing and memory deficits experienced by 
the parental APP/PSEN1 mouse strain. 
In contrast, crossing the APP/PSEN1 
mice with animals in which SIRT1 was 
deleted in the brain exacerbated AD-
type pathology and learning and mem-
ory deficits.
To determine how SIRT1 mediates 
these benefits, the investigators quanti-
fied APP and its proteolytic metabolites, 
including Aβ, in brain extracts from the 
offspring of the APP/PSEN1 and SIRT1 
cross. Along with reductions in Aβ lev-
els, APP proteolytic products from 
α-secretase cleavage were substan-
tially increased by SIRT1 overexpres-
sion, whereas those from β-secretase 
cleavage were decreased. Deletion of 
SIRT1 produced the opposite effect, 
decreasing α-secretase-mediated pro-
cessing of APP in the brain and increas-
ing brain levels of Aβ. Clear increases 
in α-secretase activity were observed 
in the SIRT1 transgenic mice, whereas 
decreases were seen in mice lacking 
SIRT1. Effects on β-secretase activity 
were rather small, suggesting that the 
changes in β-secretase-generated APP 
products were primarily indirect effects 
due to altered α-secretase activity.
Several different membrane-tethered 
proteases of the ADAM (A Disintegrin 
and Metalloprotease) family, specifically 
ADAM9, ADAM10, and ADAM17, have 
been implicated in α-secretase cleavage 
of APP (Kojro and Fahrenholz, 2005). 
However, only ADAM10 expression 
seemed to be influenced by SIRT1, with 
an increase observed upon SIRT1 over-
expression and a decrease when SIRT1 
was deleted. Because ADAM10 is also 
involved in the processing of the Notch 
receptor (Kopan and Ilagan, 2009), Don-
mez et al. (2010) examined the effects of 
SIRT1 expression on the proteolysis of 
the Notch receptor and found changes 
in NICD levels that were consistent with 
the changes seen in ADAM10 expression 
and activity. There was also increased 
expression of genes downstream of 
Notch receptor signaling in response to 
SIRT1.
But how are these beneficial effects 
of SIRT1 mediated? Analysis of the pro-
moter of ADAM10 led to identification 
of a region that directly interacts with 
SIRT1. The retinoic acid receptor (RAR) 
had been previously found to bind to this 
region and activate ADAM10 transcrip-
tion (Prinzen et al., 2005); Dommez and 
colleagues now show that RARβ is a 
specific mediator of the effects of SIRT1 
on ADAM10 expression. SIRT1 deacety-
lated RARβ and thereby activated this 
intracellular receptor. Activation of RARβ 
with its ligand retinoic acid stimulated 
ADAM10 expression and NICD pro-
duction in a SIRT1-dependent manner. 
Retinoic acid treatment also lowered Aβ 
levels, whereas an RARβ antagonist ele-
vated Aβ levels. These findings together 
suggest that RARβ activation has the 
dual effect of reducing Aβ production 
and increasing Notch signaling, both by 
promoting expression of ADAM10.
Although the detailed analyses of 
Donmez and coworkers reveal a new 
pathway for decreasing Aβ levels and 
suggest that this can simultaneously 
stimulate Notch signaling, key ques-
tions still need to be addressed before 
the therapeutic implications for treating 
human AD become clear. Retinoic acid 
is toxic in high amounts. Would specific 
RARβ agonists avoid this problem? Are Cell 142, July 23, 2010 ©2010 Elsevier Inc. 195
RARβ and SIRT1 present in regions of 
the brain most relevant to AD, such as the 
hippocampus? Would the Aβ-lowering 
effect of RARβ agonism, which is only 
partial, be sufficient to prevent or treat 
AD? What other genes are affected by 
RARβ activation, and how might they 
alter the AD phenotype? As for Notch 
signaling, the initiating step is the bind-
ing of ligand, not ectodomain shedding 
by ADAM10. Would elevation of ADAM10 
alone be sufficient to increase Notch sig-
naling in vivo? If so, would this lead to 
neuronal repair in the AD brain? Is there 
a natural ligand of APP that initiates 
shedding of the APP ectodomain, and 
would manipulating this ligand provide 
a more focused approach to increasing 
α-secretase processing of APP and thus 
reducing Aβ production? Perhaps most 
importantly, ADAM10 sheds the ectodo-
mains of many type I integral membrane 
proteins at the cell surface. What are 
the consequences, both beneficial and 
toxic, of chronically increasing ADAM10 
activity in the brain and in the periphery? 
Such questions are now worth address-
ing to assess whether this new approach 
will ultimately be able to deliver a payoff 
punch to AD.
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Four genes in the human genome have 
the SRD5A acronym, but only two of 
them, SRD5A1 and SRD5A2, encode a 
bona fide steroid 5α-reductase. The other 
two genes, SRD5A3 and SRD5A2L2, 
are posers, claiming the name despite 
having little or no functional ability to 
reduce steroid substrates. What then 
are the true substrates of these two 
pretenders? In this issue of Cell, Can-
tagrel et al. (2010) ingeniously combine 
analytical chemistry with genetics in 
humans, mice, and yeast to uncover 
the enzymatic and biological function 
of steroid 5α-reductase SRD5A3. They 
demonstrate that SRD5A3 encodes a 
polyprenol reductase that is essential 
for N-linked glycosylation of proteins in 
yeast and mammals (Figure 1A), a com-
pletely unexpected function.
SRD5A1 and SRD5A2 reduce the ∆4,5 
bond of steroid substrates using NADPH 
as a cofactor (Figure 1B) (Russell and 
Wilson, 1994). It seems that any gene 
with even a remote sequence similarity to 
SRD5A1 and SRD5A2 (such as SRD5A3, 
SRD5A2L, and others that do not use 
the SRD5A prefix) has been included in 
this family (Langlois et al., 2010). How-
ever, aside from one study on the enzy-
matic activity of SRD5A3 (Uemura et al., 
2008), experimental data on these pro-
teins has been lacking, and it is unclear 
whether steroids are indeed substrates 
of SRD5A3 and SRD5A2L.
For most steroid hormones including 
progestins and glucocorticoids, reduc-
tion of the ∆4,5 bond inactivates tran-
scriptional signaling by the hormone. 
One critical exception to this general rule 
is the reduction of the ∆4,5 bond in tes-
tosterone to produce dihydrotestoster-
one (Figure 1B). This reaction is of great 
importance during the sexual develop-
ment of males because only dihydrotes-
tosterone (not testosterone) directs the 
formation and growth of the external 
genitalia and prostate (Wilson, 1978).
Surprisingly, Cantagrel et al. (2010) find 
that steroid 5α-reductase SRD5A3 is not 
involved in steroid hormone formation or 
sexual development but instead plays a 
crucial role in the N-linked glycosylation 
of proteins. Their study begins with an 
astute clinical observation. Four children 
of a large family were born with multiple 
developmental anomalies of the eyes, 
heart, and brain. A family history revealed 
several consanguineous relationships, 
suggesting that the disease was auto-
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The steroid 5α-reductase (SRD5A) family of enzymes produces steroid hormones that regulate 
male sexual development. Now, Cantagrel et al. (2010) identify a member of this family, SRD5A3, 
as a polyprenol reductase with a crucial role in N-linked protein glycosylation and pinpoint SRD5A3 
mutations as the cause of a rare Mendelian disease.
